Cargando…
Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
Weekly administration of nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) has been shown to be a safe and effective treatment for metastatic breast cancer (MBC) in clinical studies. We conducted a multicenter, randomized, open‐label phase II study to compare the efficacy and safety of weekly n...
Autores principales: | Tamura, Kenji, Inoue, Kenichi, Masuda, Norikazu, Takao, Shintaro, Kashiwaba, Masahiro, Tokuda, Yutaka, Iwata, Hiroji, Yamamoto, Naohito, Aogi, Kenjiro, Saeki, Toshiaki, Nakayama, Takahiro, Sato, Nobuaki, Toyama, Tatsuya, Ishida, Takanori, Arioka, Hitoshi, Saito, Mitsue, Ohno, Shinji, Yamauchi, Hideko, Yamada, Kimito, Watanabe, Junichiro, Ishiguro, Hiroshi, Fujiwara, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448660/ https://www.ncbi.nlm.nih.gov/pubmed/28256066 http://dx.doi.org/10.1111/cas.13221 |
Ejemplares similares
-
Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
por: Watanabe, Toru, et al.
Publicado: (2017) -
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer
por: Inoue, Kenichi, et al.
Publicado: (2015) -
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021) -
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019) -
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)